Skip to main content
. 2024 Jul 16;20(2):230192. doi: 10.1183/20734735.0192-2023

FIGURE 3.

FIGURE 3

The interaction between T-cells, dendritic cells and cancer cells is shown, with the role of the pathways programmed death-ligand 1 (PD-L1)–programmed death-1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA4)–B7/CD28 binding as negative regulators of T-cell immune function. Pharmacological agents that alter these interactions (see boxes) enhance the T-cell driven anti-tumour response. Reproduced and modified from [29] with permission.